PTN — Palatin Technologies Share News
0.000.00%
Last trade - 00:00- $9.10m
- $1.61m
- $13.19m
Brief: Palatin Technologies Reports Q2 Fiscal Year 2021 Financial Results And Recent Business Highlights
Brief: Palatin Technologies Announces Filing Of International Patent Application Claiming PL9643
Brief: Palatin Technologies Announces Positive Results From Phase 2 Study Of Pl9643 In Patients With Dry Eye Disease
Brief: Palatin Technologies Inc Reports First Quarter Fiscal Year 2021 Results And Provides Business Update
Brief: Palatin Technologies Reports Q1 Loss Per Share $0.02
AMEX HALT EQUIPMENT CHANGEOVER LAST 0.390100
Brief: Palatin Technologies Reports Q4 Loss Per Share Of $0.03
Brief: Palatin Completes Enrollment Of Phase 2 Study With Pl9643 For Dry Eye Disease
Brief: Palatin Technologies Announces Mutual Termination Of License Agreement With AMAG Pharmaceuticals For Vyleesi
Brief: Palatin Technologies Announces Reinitiation Of Enrollment Of Phase 2 Study With Pl9643 For Treatment Of Dry Eye Disease
Palatin Technologies: Jumps as drugmaker says developing potential COVID-19 treatment
Brief: Palatin Technologies To Develop Pl8177 As A Potential Treatment For Covid-19
Brief: Palatin Technologies Reports Q3 Loss Per Share $0.02
Brief: Palatin Technologies Inc - Cash And Cash Equivalents Of $88.9 Million As Of March 31, 2020
Brief: Palatin Tech Announces First Patient Enrolled In Dry Eye Disease Phase 2 Clinical Trial With Pl9643
Brief: Palatin Technologies Q2 Loss Per Share $0.02
Brief: Palatin Technologies Says Dry Eye Disease Phase 2 Study To Commence Q1 2020
Brief: Palatin Technologies Reports Q1 Loss Per Share Of $0.02
Brief: Palatin Technologies Q4 Earnings Per Share $0.23